Myocardial perfusion imaging and cardiovascular outcomes in a cancer population

Texas Heart Institute Journal

Volumn 36, Issue 3, 2009, Pages 205-213

  Chandra, Shalabh ^a   Lenihan, Daniel J ^a   Wei, Wei ^a   Yusuf, Syed Wamique ^a   Tong, Ann T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Aspirin therapeutic use; Comorbidity; Coronary disease epidemiology radionuclide imaging; Death, sudden, cardiac prevention control; Electrocardiography; Exercise test methods statistics numerical data; Heart radionuclide imaging; Multivariate analysis; Neoplasms epidemiology mortality; Predictive value of tests; Proportional hazards model; Retrospective studies; Risk assessment methods; Ventricular function, left

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TETROFOSMIN TC 99M; THALLIUM CHLORIDE TL 201;

ADULT; AGED; ARTICLE; CANCER PATIENT; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CORRELATION ANALYSIS; DRUG UTILIZATION; EVENT FREE SURVIVAL; FEMALE; GROUPS BY AGE; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HEART SCINTISCANNING; HUMAN; HYPERLIPIDEMIA; IMAGE ANALYSIS; IMAGING SYSTEM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SMOKING; SURVIVAL RATE;

AGE FACTORS; AGED; ASPIRIN; ATRIAL FIBRILLATION; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SMOKING; STROKE VOLUME; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 67650424314     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Berman DS, Hachamovitch R, Kiat H, Cohen I, Cabico JA, Wang FP, et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography [published erratum appears in J Am Coll Cardiol 1996;27(3):756]. J Am Coll Cardiol 1995;26(3):639-47.
2. Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction [published erratum appears in Circulation 1998;98(2):190]. Circulation 1998;97(6):535-43.
3. Galassi AR, Azzarelli S, Tomaselli A, Giosofatto R, Ragusa A, Musumeci S, et al. Incremental prognostic value of technetium-99m-tetrofosmin exercise myocardial perfusion imaging for predicting outcomes in patients with suspected or known coronary artery disease. Am J Cardiol 2001;88(2):101-6.
4. Schinkel AF, Elhendy A, Biagini E, van Domburg RT, Valkema R, Rizello V, et al. Prognostic stratification using dobutamine stress 99mTc-tetrofosmin myocardial perfusion SPECT in elderly patients unable to perform exercise testing. J Nucl Med 2005;46(1):12-8.
5. Lima RS, De Lorenzo A, Pantoja MR, Siqueira A. Incremental prognostic value of myocardial perfusion 99m-technetiumsestamibi SPECT in the elderly. Int J Cardiol 2004;93(2-3): 137-43.
6. De Lorenzo A, Lima RS, Siqueira-Filho AG, Pantoja MR. Prevalence and prognostic value of perfusion defects detected by stress technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography in asymptomatic patients with diabetes mellitus and no known coronary artery disease. Am J Cardiol 2002;90(8):827-32.
7. Pryma DA, Ravizzini G, Amar D, Richards VL, Patel JB, Strauss HW. Cardiovascular risk assessment in cancer patients undergoing major surgery. J Nucl Cardiol 2005;12(2):151-7.
8. ASCO.org [homepage on the Internet]. American Society of Clinical Oncology; Alexandria, VA: c2005-9 [cited 2009 Feb 17]. Available from: http://www.asco.org/portal/site/ASCO.
9. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004;291(20):2441-7.
10. Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. J Clin Epidemiol 1999;52(12):1131-6.
11. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol 2007;49(16):1740-9.
12. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003;290(19):2581-7.
13. Chang K, Sarkiss M, Won KS, Swafford J, Broemeling L, Gayed I. Preoperative risk stratification using gated myocardial perfusion studies in patients with cancer. J Nucl Med 2007;48(3):344-8.
14. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/ WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50(22):2173-95.
15. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/ AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 2003;42(7):1318-33.
16. Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina) [published erratum appears in J Am Coll 1999;34(1):314]. J Am Coll Cardiol 1999;33(7):2092-197.
17. Gibbons RJ. Myocardial perfusion imaging. Heart 2000; 83(3):355-60.
18. Shaw LJ, Hachamovitch R, Heller GV, Marwick TH, Travin MI, Iskandrian AE, et al. Noninvasive strategies for the estimation of cardiac risk in stable chest pain patients. The Economics of Noninvasive Diagnosis (END) Study Group. Am J Cardiol 2000;86(1):1-7.
19. Sarkiss MG, Yusuf SW, Warneke CL, Botz G, Lakkis N, Hirch-Ginsburg C, et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer 2007;109(3):621-7.
20. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109(25):3122-31.
21. Romero L, de Virgilio C. Preoperative cardiac risk assessment: an updated approach. Arch Surg 2001;136(12):1370-6.
22. Ho KT, Miller TD, Hodge DO, Bailey KR, Gibbons RJ. Use of a simple clinical score to predict prognosis of patients with normal or mildly abnormal resting electrocardiographic findings undergoing evaluation for coronary artery disease. Mayo Clin Proc 2002;77(6):515-21.
23. Torres MR, Short L, Baglin T, Case C, Gibbs H, Marwick TH. Usefulness of clinical risk markers and ischemic threshold to stratify risk in patients undergoing major noncardiac surgery. Am J Cardiol 2002;90(3):238-42.
24. Alkeylani A, Miller DD, Shaw LJ, Travin MI, Stratmann HG, Jenkins R, Heller GV. Influence of race on the prediction of cardiac events with stress technetium-99m sestamibi tomographic imaging in patients with stable angina pectoris. Am J Cardiol 1998;81(3):293-7.